These novel therapies , Tirzepatide , represent a groundbreaking advancement in addressing metabolic dysfunction and possibly other conditions . These drugs are categorized as GLP-1 pathway activators https://aoifehvlg164524.iyublog.com/40193222/retatrutide-a-thorough-examination-into-incretin-agents